恒河猴实验感染庚型肝炎病毒的实验研究

目的研究庚型肝炎病毒（ＨＧＶ）在恒河猴中的实验感染状态。方法用一名ＨＧＶＲＮＡ阳性、ＨＢＶ、ＨＣＶ均阴性的健康献血员血浆实验感染２只恒河猴，并取第一代猴感染后６周的血再感染１只第二代恒河猴，然后用以第二代猴感染６周后血继续感染２只第三代恒河猴。分别用逆转录聚合酶链反应（ＲＴ－ｎＰＣＲ）检测受感染猴血清中的ＨＧＶＲＮＡ，并每周抽血测定血清中丙氨酸转氨酶（ＡＬＴ）。结果感染１周后猴血清ＨＧＶＲＮＡ阳转，最长持续阳性２８周以上。不同感染个体血清ＡＬＴ水平有明显差异，其中１号猴有短期轻度升高，５号猴血清ＡＬＴ较长时间在１００Ｕ／Ｌ以上。肝活检发现，感染后１６周猴肝组织出现明显的病毒性肝炎样病理改变。进一步对该献血员血浆和感染后猴血清中的ＨＧＶ５’端部分非编码区基因ＰＣＲ产物进行测序，结果显示感染用献血员血浆和猴血清中ＨＧＶ序列与国外株ＨＧＵ４４４０２的同源性分别为９８３３％和９５８３％；与ＨＧＵ３６３８０株的同源性分别为９２５０％和８９１７％；感染猴血清中ＨＧＶ序列与献血员ＨＧＶ序列同源性为９５８３％。结论恒河猴对ＨＧＶ敏感，可以做为实验模型动物     

肝病患者中庚型肝炎病毒感染的检测

目的探讨临床肝病病人中庚型肝炎病毒（ＧＢＶ－Ｃ／ＨＧＶ）感染情况及临床特点。方法应用庚型肝炎病毒基因组５’ＵＴＲ两对寡核苷酸作为引物，建立逆转录套式聚合酶链反应，检测１６９例不同肝病患者血清标本中ＧＢＶ－Ｃ／ＨＧＶＲＮＡ，并对其中１例ＰＣＲ扩增产物进行克隆及测序。结果１６９例各型肝病病人ＧＢＶ－Ｃ／ＨＧＶＲＮＡ总的检出率为９５％（１６／１６９）。在２９例有手术输血史患者中，３１０％（９／２９）ＧＢＶ－Ｃ／ＨＧＶＲＮＡ呈阳性，明显高于无手术输血史组（５％，Ｐ＜００１）。序列分析显示１株庚肝病毒５’ＵＴＲ部分基因片段与已知庚肝病毒株核苷酸同源性在８９１４％～９８９１％之间。结论ＧＢＶ－Ｃ／ＨＧＶ感染普遍存在于临床肝病患者中，病人感染ＧＢＶ－Ｃ／ＨＧＶ的临床表现未发现有特殊性，ＧＢＶ－Ｃ／ＨＧＶ可能不是非甲～戊型肝炎的主要致病因子。     

庚型肝炎病毒5‘非编码区基因分析及基因型的初步划分

为了分析我国庚型肝炎病毒（ＨＧＶ）的基因结构特点，对２名个体供血者、２例慢性肝炎患者及２例肝硬化患者的血清标本进行了庚型肝炎病毒基因组５’非编码区２７７个核苷酸的基因扩增、分子克隆和序列分析，并利用基因分析软件处理结果。结果表明，分离出的６株ＨＧＶ５’非编码区基因序列（Ｇ００１～Ｇ００６）之间同源性在９６．２％以上。而与国外报道的３株ＨＧＶ序列比较同源性在８６．９％～９１．６％。通过对６株ＨＧＶ（Ｇ００１～Ｇ００６）及国外报道的３株ＨＧＶ基因序列变异性的比较，将ＨＧＶ基因型初步划分为不同的３个组。结果提示我国ＨＧＶ株５’非编码区序列有较高的同源性，而与国外报道的有较大差异，但不同毒株在此区域均可能形成稳定而相似的二级结构模式。     

庚型肝炎病毒NS5区基因序列测定和分析

目的为了研究哈尔滨市庚型肝炎病毒（ＨＧＶ）非结构（ＮＳ５）区基因结构特征。方法对阳性标本进行了庚型肝炎病毒ＮＳ５区１８６核苷酸的基因扩增、分子克隆和序列分析，并利用基因分析软件处理结果。结果分离出的２株ＨＧＶＮＳ５区基因序列之间同源性为９５２％，而与国外报道的３株ＨＧＶ序列比较同源性在８４４％～９２４％，变异较大。结论提示ＨＧＶ有不同的基因型，这有待于对各区基因序列进行全面检测，综合判断之后才能确定。分离出的阳性株为从１９８４年肝炎患者血中分离，肯定了我市在８０年代就有庚型肝炎病毒感染存在     

35例庚型肝炎临床及酶学变化观察

目的探讨庚型肝炎病毒（ＨＧＶ）感染的临床意义。方法应用逆转录－套式聚合酶链反应（ＲＴ－ｎＰＣＲ）检测１６５例肝炎患者血清ＨＧＶＲＮＡ和血清酶的变化。其中急性肝炎２４例，慢性肝炎７８例，肝硬化１８例，肝癌４例，乙、丙肝携带者４１例。结果在急性黄疸型肝炎中检出单纯性ＨＧＶ感染３例（１２５％），血清ＡＬＴ水平在４８８±６５Ｕ／Ｌ之间，ＡＳＴ在４５２±７１Ｕ／Ｌ之间，ＴＢｉＬ在７７１±１４３μｍｏｌ／Ｌ。急性肝炎酶的升高一般在１个月内降到正常，而ＨＧＶＲＮＡ在ＡＬＴ降到正常后仍持续一段时间才转阴，其中１例发病后９个月转阴。慢性肝炎中检出ＨＧＶＲＮＡ阳性１９例（２４４％），其中单纯性ＨＧＶ阳性４例（５１３％）。肝硬化肝癌中ＨＧＶＲＮＡ阳性４例，其中１例肝硬化为单纯性ＨＧＶ阳性。结论在急性黄疸型肝炎、乙型肝炎病毒携带者、慢性肝炎、肝硬化以及肝癌中均可检出庚型肝炎病毒，为单独感染或与乙、丙型肝炎病毒同时或重叠感染，其传播途径与乙、丙型肝炎的传播途径相同。     

深圳地区不同人群庚型肝炎病毒感染的分子流行病学调查

在庚型肝炎病毒（ＨＧＶ）基因５’端非编码区（５’－ＵＴＲ）设计两对套式引物，建立检测ＨＧＶＲＮＡ的逆转录－巢式聚合酶链反应（ＲＴ－ｎｅｓｔｅｄＰＣＲ）。对深圳地区１０６例职业献血员、１６８例肝炎病人及８０例静脉毒瘾者进行ＨＧＶＲＮＡ的检测，阳性率分别为８．５％、７．７％与４６．３％，前两者与后者相比较差异均有显著性意义（Ｐ＜０．０１）。６１例慢性乙型肝炎与３３例慢性丙型肝炎病人ＨＧＶＲＮＡ阳性率分别为８．２％与２１．２％。３３例慢性丙型肝炎病人中，１５例接触过血液或血制品的病人ＨＧＶＲＮＡ阳性率为４０．０％，明显高于１８例无血液或血制品接触史者（Ｐ＜０．０５）。本研究结果提示深圳地区职业献血员中ＨＧＶ携带者较常见；静脉毒瘾者是ＨＧＶ感染的高危人群；慢性丙型肝炎常重叠ＨＧＶ感染，主要与接触血液或血制品有关。故对献血员进行ＨＧＶ筛查将减少输血后ＨＧＶ感染的发生     

合成肽作抗原酶免疫技术检测非甲－戊型肝炎病人血清中抗HGV

本文应用人工合成肽作为抗原建立了检测庚型肝炎病毒（ＨＧＶ）抗体的酶免疫技术（ＥＩＡ），最适抗原包被浓度为４μｇ／ｍｌ。在特异性验证的基础上，检测了３４例非甲－戊５型肝炎病人血清和３２例丙型肝炎感染病人血清。结果表明，在ＨＧＶ感染高危人群中，诸如输血后肝炎－丙型肝炎中有较高的ＨＧＶ的感染率。本方法的建立为临床上难于作出诊断的庚型肝炎提供了敏感、特异、易于应用的新技术。     

丙型肝炎病毒与庚型肝炎病毒混合感染及其对干扰素治 …

目的 研究丙型肝炎患者中庚型肝炎病毒（ＨＧＶ）混合感染情况。方法 采用套式聚合酶链反应（ＰＣＲ）方法检测血清样本中的ＨＧＶ ＲＮＡ。结果 ６０例丙型肝炎患者血清中的ＨＧＶ ＲＮＡ阳性率为２３．３％，其中慢性丙型肝炎患者的ＨＧＶ阳性率高于急性丙型肝炎患者。本组病例中，ＨＧＶ感染仅见于有输血或血制品史的患者。结论 血液传播是ＨＧＶ感染的主要途径。ＨＧＶ的感染有可能导致输血后丙型肝炎的潜伏期缩短。在α－     

献血员、丙型肝炎患者血中庚型肝炎检测分析

庚型肝炎病毒（ＨＧＶ） ,主要是经血液传播的一种新型肝炎病毒 ,对献血员进行ＨＧＶ筛查 ,是避免和减少与ＨＧＶ相关的输血性肝炎发生的有效方法。本文通过对献血员及丙型肝炎患者血清中抗ＨＧＶ -ＩｇＧ及庚型肝炎病毒核酸（ＨＧＶ -ＲＮＡ）的检测 ,对其感染状况进行分析 ,现将结果报告如下。对象和方法一、对象 :健康对照组８５例 ,用ＲＩＡ作血ＨＢｓＡｇ、ＨＣＶ -ＩｇＧ检测均为阴性 ,ＡＬＴ正常 ,年龄２１～３８岁。献血员１２６例 ,年龄２３～４２岁。丙型肝炎患者８６例（发病前均有输血史 ,根据１９９５年第五次全国病毒性肝炎诊…     

华南地区HGV的流行状况和同源性分析

目的了解华南地区庚型肝炎病毒（ＨＧＶ）的流行状况及ＨＧＶ不同株和不同基因区的同源性。方法采用逆转录聚合酶链反应技术（ＲＴ－ＰＣＲ）检测来自广东、香港、云南的不同人群血清标本共１９９１份。对其中２０份的５端非编码区（５ＵＴＲ）２３８ｂｐ和３份非结构蛋白５区（ＮＳ５）６２１ｂｐ进行了序列测定和同源性分析。结果一般人群ＨＧＶＲＮＡ阳性率为（０．７３～１．３４）％,献血员（２．５２～２．９０）％,静脉吸毒者１７．８６％,血液透析患者１４．１３％,接受骨髓移植者４１．６７％,在非甲～戊型肝炎病人为２５．３０％,肝细胞癌１４．４８％,乙型肝炎７．２２％,丙型肝炎（８．３３～１６．１３）％。不同株５ＵＴＲ同源性介乎（９０．４０～１００）％;不同株ＮＳ５区核苷酸同源性（９３．３０～９４．００）％,氨基酸为（９７～９９．２）％。结论接受骨髓移植、血液透析、静脉吸毒者,乙型、丙型、非甲～戊型肝炎病人及肝细胞癌患者是ＨＧＶ的高感染人群。不同ＨＧＶ株存在一定的地区性差异;同一地区不同人群的ＨＧＶ株变异不明显;序列中存在高度保守区及较大变异区     

深圳地区不同人群庚型肝炎病毒感染的分子流行病…

在庚型肝炎病毒（ＨＧＶ）基因５’端非编码区（５’－ＵＴＲ）设计两对套式引物，建立检测ＨＧＶＲＮＡ的逆转录－巢式聚合酶链反应（ＲＴ－ｎｅｓｔｅｄＰＣＲ）。对深圳地区１０６例职业献血员，１６８例肝炎病人及８０例静脉毒瘾者进行ＨＧＶＲＮＡ的检测，阳性率分别为８．５％，７．７％与４６．３％前两者与后者相比较差异均有显著性意义（Ｐ〈０．０１）。６１例慢性乙型肝炎与３３例慢性丙型肝炎病人ＨＧＶＲＮＡ阳性率分别     

GBV-C/hepatitis G virus in acute nonA-E hepatitis and in acute hepatitis of defined aetiology in Italy

The role of GBV-C/HGV in the aetiology of acute non A-E hepatitis and its impact on the course of acute hepatitis of defined aetiology were investigated by detecting viral RNA by RT-PCR and antibody to the E2 protein of GB virus C (anti-E2) by EIA. Ninety-eight patients with acute nonA-E hepatitis, 35 patients with acute hepatitis A, 63 with acute hepatitis B, 29 with acute hepatitis C and 270 controls were enrolled in this study. The prevalence of GBV-C/HGV RNA was similar among patients with acute nonA-E hepatitis (3.1%), with acute hepatitis A (2.9%), and controls (3.7%), but significantly higher (P < 0.05) among those with hepatitis B or C (19.0% and 48.3%, respectively). Similar figures were obtained considering the total rate of GBV-C/HGV exposure (viral RNA or anti-E2 positivity). The majority (24/30 or 80%) of GBV-C/HGV RNA positive patients reported a parenteral source of exposure whereas the remaining 20% denied having known risk factors. The liver function test values and the rate of chronic hepatitis B and C were similar in patients co-infected and in those not co-infected with GBV-C/HGV. This study excludes a significant role of GBV-C/HGV infection in the aetiology of acute nonA-E hepatitis in Italy. Concomitant GBV-C/HGV and HBV or HCV infection does not worsen the clinical course of illness among patients with acute hepatitis.     

Detection of hepatitis G virus RNA in patients with hepatitis B,hepatitis C,and non-A-E hepatitis by RT-PCR using multiple primer sets

Hepatitis G virus(HGV)/GB virus C(GBV-C) is a newly identified virus associated with human hepatitis. The preliminary prevalence studies of HGV infection in Japan were entirely based on the detection of HGV RNA by RT-PCR. However, the selection of the different primer sets in such assay may influence sensitivity of the test because of the extensive genetic heterogeneity of HGV, and influence the estimation of the prevalence of HGV. To address this potential problem, we designed two primer sets from well conserved domains in the 5′NC and NS5 regions of HGV genome, and tested them together with the NS3-derived primer set in RT-PCR for their ability to detect HGV RNA in serial dilution of synthetic viral RNA templates. Subsequently, we used these three primer sets to detect HGV RNA in the sera of 371 Japanese patients with hepatitis B, hepatitis C, and non-A-E hepatitis. The results indicated that the primer set derived from the 5′NC region appeared to be most effective in detecting HGV RNA. The results also showed that only two out of the 126 patients (1.6%) with non-A-E hepatitis were positive for HGV RNA although the RNA were detected more frequently in patients with hepatitis B (2/38; 5.3%) and hepatitis C (17/207; 8.2%), suggesting that HGV is not a common causative agent for non-A-E hepatitis in Japan. J. Med. Virol. 52:385–390, 1997. © 1997 Wiley-Liss, Inc.     

GBV-C/HGV infection in chronic hepatitis C patients: Its effect on clinical features and interferon therapy

A novel virus (GBV-C/HGV) may be associated with some liver diseases including fulminant hepatitis and acute and chronic hepatitis. On the other hand, many investigations showed that this infection does not contribute to liver disease. GBV-C/HGV has been found to occur in association with infection with other hepatitis viruses. We investigated the effect of GBV-C/HGV infection on the clinical features and interferon treatment in patients with chronic hepatitis C. A total of 262 hepatitis C virus (HCV) RNA positive patients with chronic hepatitis were examined in this study. The detection of serum GBV-C/HGV RNA was done by RT-PCR using specific primers from the NS5 regions. Interferon-alpha was given at a dose of 6 MU/day for 16 or 24 weeks. A responder was defined as a patient with ALT normalization and HCV RNA disappearance after treatment. GBV-C/HGV RNA was detected in 28 (11%) patients. No significant difference was detected in clinical features (age, sex, liver-related biochemical tests, and histological examination) between the 28 GBV-C/HGV-positive patients and the GBV-C/HGV-negative patients. Using interferon therapy for hepatitis C, the responder rates of GBV-C/HGV-positive and -negative patients were 14% and 20%, respectively. Of the 28 patients with GBV-C/HGV RNA, GBV-C/HGV RNA was tested after interferon therapy in 16 and of these GBV-C/HGV RNA was not detected in nine patients after therapy. These findings suggest that GBV-C/HGV infection dose not affect the clinical features in patients with HCV and the efficacy of interferon therapy for chronic hepatitis C. J. Med. Virol. 55:98–102, 1998. © 1998 Wiley-Liss, Inc.     

用逆转录—套式聚合酶链反应检测我国不同临床型肝？…

目的 为了研究庚型肝炎病毒（ＨＧＶ）在我国的感染状况。方法 概括已发表的ＨＧＶ的５‘端非编码区（５’－ＵＴＲ区）及螺旋酶区（ＮＳ３区）两段高度保守的基因序列分别设计两套引物，用逆转录－套式聚合酶链式反应检测ＨＧＶＲＮＡ。结果 从北京、秦皇岛、河南等地采集各种肝病患者及职业献血员血清３５４份，ＨＧＶＲＮＡ阳性９７份，阳性率为２２．３％。其中已确定的临床型肝炎／肝病患者２５４例，ＨＧＶＲＮＡ阳性者为５     

广西HCV高危人群庚型肝炎病毒的新基因型核苷酸序列分析

目的 探讨广西HCv高危人群庚型肝炎病毒(HGv)的感染情况及其新基因型的核苷酸序列。方法 静脉药瘾者(IVDAs)85份、肝病患者(PLDs)80份和献血员(BDs)50份血清标本．用PCR法检测庚型肝炎病毒RNA，EIA法检测HBsAg、抗-HCV和抗-HIV；随机选出62份庚型肝炎病毒RNA阳性标本进行核苷酸序列分析，构建种系发生树作基因分型。结果 215份血清中HGv阳性者85份(39.53％)，HBsAg、抗-HGV和抗-HIV的阳性率分别为39.07％、42．79％和0；11份HGV RNA的测序结果证实其有3种基因型，其中5株为新基因型(亚洲型)，51份补测序，其中GBV—C型占3．23％，HGV型占30.65％，亚洲型占64．51％。结论 HGV的3种基因型中存在不同的基因亚型；广西IVDAs、PLDs和BDs中感染庚型肝炎病毒以亚洲型和HGV型为主。